Skip to main content

IMMUCELL CORP /DE/

For the period ended Dec 31, 2025. Filed Mar 30, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 30, 2026

ICCC$10.22+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 2. Properties

Location/DescriptionFunction/UseApproximate Square FeetLease/Own
56 Evergreen Drive, Portland, Mainei) principal executive office and laboratory needs, ii) vaccine manufacturing operations, iii) liquid processing operations and iv) freeze-drying operations for our USDA-regulated product line.34,850Own
33 Caddie Lane, Portland, Maine(1)Re-Tain® FDA-regulated operations16,202Own
14 Wedge Way, Portland, MaineWarehouse space primarily for storage of inventory, materials and equipment4,080Own
175A Industrial Way, Portland, MaineAll of our powder milling and filling, gel formulation and assembly services.14,300Lease
175B Industrial Way, Portland, Mainei) additional warehouse space, ii) shipping and receiving services from 56 Evergreen Drive and iii) space for additional freeze-drying equipment in the future to increase our production capacity15,400Lease

(1) At the end of December 2025, the Company made the decision to cease further investment in its Re-Tain® manufacturing operations. As a result, we intend on refitting this building to meet the manufacturing needs of our First Defense® product line.

In addition to the properties above, we also lease office, storage and parking space in New York and a small sales office in Winona, Minnesota. We maintain property insurance in amounts that approximate replacement cost and a modest amount of business interruption insurance.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.